Michele Bianchini
B, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Journal: Leukemia
Published: September 08, 2025
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.
Journal: Journal of hematology & oncology
Published: January 16, 2023
Development of an inverse-PCR approach for characterization of the major BCR-ABL1 breakpoint sequences on genomic DNA: proof of concept.
Journal: Clinical chemistry and laboratory medicine
Published: October 06, 2020
miRNome profiling of LSC-enriched CD34+CD38-CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.
Journal: Frontiers in pharmacology
Published: September 30, 2020
Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations.
Journal: Clinical chemistry and laboratory medicine
Published: December 12, 2019
Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia.
Journal: Oncotarget
Published: September 01, 2017
Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR
Journal: Medicina
Published: February 01, 2017
Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells.
Journal: Oncology reports
Published: September 27, 2016
Last Updated: 09/26/2026